PTH-097 Cognitive behavioural responses and quality of life in stable patients on biologics: an unmet need in ibd?

2017 
Introduction Physician and patient preferences (particularly for the route of administration; RoA) are central to uptake and adherence of biologic therapy in IBD. While patients reportedly prefer subcutaneous (SC) administration [1], there remains a significant cohort who select intravenous (IV) therapy if offered. This cohort study was conducted to elicit psychosocial factors associated with the route of biologic administration. Method Patients offered a free choice of RoA, with quiescent disease were identified from our electronic database: optimised, stable dose of biologic and no use of corticosteroids, for ≥3 months; normal B12, ferritin and vitD serum level; faecal calprotectin Results 24 patients were on adalimumab (SC group; 13F, 36.0±12.3 years, 5UC), with 25 on Remicade (IV group: 17F, 38.5±13.4 years (IV group). There were no significant differences in demographics, or numbers of patients reporting PHQ-9 or GAD-7 scores>10 (moderate symptoms), but 11 (22%) exceeded this cut-off. MHLC responses were identical, while SC patients report lower IBDC (7 vs 9, p Conclusion SC patients were significantly more unhelpfully focused on symptoms (“I think a great deal about my symptoms”) and catastrophising (“I will never feel right again”) as well as reporting engaging in behaviours to avoid embarrassment. Despite quiescent disease, ‘unhelpful’ higher CBRSQ scores correlated with worse disease-related QOL (p References . Vavricka SR, et al. Inflamm Bowel Dis2012:18:523–530 . Bodger K, et al. Gut2015;63:1092–1102 Disclosure of Interest None Declared
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []